[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346294-105":59,"doc-detail-346294-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-broad-spectrum-of-cancer-and-immunotherapy-achievements-and-limitations-review","The broad spectrum of cancer and immunotherapy: achievements and limitations - Review","","Cancer immunotherapy has transformed oncology by enabling treatments for previously untreatable malignancies. The article reviews three major strategies—immune checkpoint blockade, adoptive cell therapy such as CAR-T, and cancer vaccines—and explains how they activate anti-tumor immunity. It also details persistent barriers, especially for solid tumors, including tumor resistance, off-target toxicities, manufacturing complications, and inter-patient outcome variability. The review summarizes advances and key challenges, emphasizing reinforcement of adaptive immunity while also covering innate immune modulation alternatives.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-broad-spectrum-of-cancer-and-immunotherapy-achievements-and-limitations-review/346294/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-broad-spectrum-of-cancer-and-immunotherapy-achievements-and-limitations-review/346294.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the three main strategies of cancer immunotherapy discussed in the review?","Question",{"text":112,"@type":113},"The review categorizes cancer immunotherapy into immune checkpoint blockade, adoptive cell therapy (including CAR-T), and cancer vaccines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are immune checkpoint inhibitors effective?",{"text":117,"@type":113},"They boost anti-tumor immune responses by blocking immunosuppressive signals used by cancer cells to evade immune surveillance, particularly those affecting cytotoxic T lymphocytes.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges limit the effectiveness of cancer immunotherapy, especially for solid tumors?",{"text":121,"@type":113},"Key challenges include development of tumor resistance, off-target effects causing adverse side effects, manufacturing complications, and variability in clinical outcomes among patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346294,1790813876,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Review  \nPUBLISHED 12 January 2026  \nDOI 10.3389/fimmu.2025.1697505  \nOPEN ACCESS  \nEDITED BY  \nAna Carolina Martinez-Torres, Autonomous University of Nuevo Leo´n, Mexico  \nREVIEWED BY  \nRaul Rangel,  \nAutonomous University of Nuevo Leo´n, Mexico  \nAlejandra Reyes Ruiz,  \nThe Rockefeller University, United States  \n*CORRESPONDENCE  \nPablo Herna´ndez-Camarero  \n [phernand@ujaen.es](phernand@ujaen.es)[ ](phernand@ujaen.es)Manuel Picon-Ruiz  \n [mpicon@ugr.es](mpicon@ugr.es)  \n†These authors have contributed equally to this work  \nRECEIVED 02 September 2025  \nREVISED 12 December 2025  \nACCEPTED 22 December 2025  \nPUBLISHED 12 January 2026  \nCITATION  \nAman A, Toledo B, Gonza´lez-Titos A, Picon-Ruiz M and Herna´ndez-Camarero P (2026) The broad spectrum of  \ncancer and immunotherapy:  \nachievements and limitations.  \nFront. Immunol. 16:1697505 .  \ndoi: 10.3389/fimmu.2025.1697505  \nCOPYRIGHT  \n© 2026 Aman, Toledo, Gonza´lez-Titos, Picon-Ruiz and Herna´ndez-Camarero. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe broad spectrum of  \ncancer and immunotherapy: achievements and limitations  \nArifa Aman 1,2†, Bel´en Toledo 1,3,4†, Aitor Gonz´alez-Titos 1,5,6, Manuel Picon-Ruiz 1,5,6,7* and Pablo Hern´andez-Camarero 1,3*  \n1 Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, Granada, Spain, 2ASA Research Ventures Private Limited, Lahore, Pakistan,  \n3 Department of Health Sciences, University of Jae´n, Jae´n, Spain, 4 Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center (UMC), Vrije Universiteit University, Amsterdam, Netherlands, 5 Unit “Modeling Nature” (MNat), University of Granada, Granada, Spain,  \n6 Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, Spain, 7 Instituto de Investigacio´n Sanitaria ibs. GRANADA, Granada, Spain  \nCancer immunotherapy has revolutionized cancer treatment over the past decades, offering renewed hope to patients with previously untreatable malignancies. This therapeutic approach could be categorized into three primary strategies: immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immune checkpoint inhibitors have been highly successful in boosting anti-tumour immune responses by blocking the immunosuppressive signals that cancer cells exploit to evade immune surveillance, mainly that exerted by cytotoxic T lymphocytes. Adoptive cell therapy, particularly chimeric antigen receptor (CAR)-T cell therapy, involves the infusion of genetically modiﬁed cytotoxic T cells to speciﬁcally target tumour cells, showing particular efﬁcacy in hematological malignancies. Cancer vaccines have also emerged as a promising strategy, eliciting anti-tumour responses via the patient ’ s own immune system . Despite these advancements, several challenges persist, particularly in the treatment of solid tumours. These include the development of tumour resistance, off-target effects that lead to adverse side effects, manufacturing complications, and variability in patient clinical outcomes. Overcoming these limitations will require further research and innovation to optimize the clinical translation of immunotherapy and broaden its application toward more personalized medicine. This review highlights the advancementsand key challenges in the mentioned cancer immunotherapy strategies, with a special emphasis on the reinforcement of adaptive immune system against tumour cells. Additionally, some alternative approaches relying on the modulation of innate immune syste","cbCaibsbn0u3Wmrp","https://ap.wps.com/l/cbCaibsbn0u3Wmrp","pdf",7044595,22,"English","# Introduction\n## Cancer–immunity connection\n## Cancer immunotherapy strategies\n## Immune checkpoint inhibitors\n## Therapeutic mechanisms and response variability","[{\"question\":\"What are the three main strategies of cancer immunotherapy discussed in the review?\",\"answer\":\"The review categorizes cancer immunotherapy into immune checkpoint blockade, adoptive cell therapy (including CAR-T), and cancer vaccines.\"},{\"question\":\"Why are immune checkpoint inhibitors effective?\",\"answer\":\"They boost anti-tumor immune responses by blocking immunosuppressive signals used by cancer cells to evade immune surveillance, particularly those affecting cytotoxic T lymphocytes.\"},{\"question\":\"What challenges limit the effectiveness of cancer immunotherapy, especially for solid tumors?\",\"answer\":\"Key challenges include development of tumor resistance, off-target effects causing adverse side effects, manufacturing complications, and variability in clinical outcomes among patients.\"}]","The broad spectrum of cancer and immunotherapy: achievements and limitations - Review | PDF",1790060815,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/065a09bd8b074b2191da4ed63da410fa.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/695549e2dcf9e637dbbae11432c4806e.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6a9e57e2f55f923019e813e48c51001.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbce0c66a49b75c19110a0847384414c.webp",980,1385]